Accelerating Pre-Clinical Large-Molecule Screening with an Integrated DMPK/ADME Approach

In early discovery and development, accurate bioanalytical methods, combined with CMC manufacturability, are essential for driving molecule screening and assessing developability within a DMPK/ADME framework.

In this webinar, we will present case studies spanning multiple novel modalities including antibodies, bispecific antibodies, ADC (Antibody Drug Conjugate), and APC (Antibody Peptide Conjugate) therapeutics. The presentation will focus on three key areas:

These case studies demonstrate how an integrated DMPK/ADME platform can accelerate preclinical screening and improve decision-making for early-stage large-molecule programs. While bioanalysis of biologics and conjugated therapeutics presents unique challenges due to matrix complexity, molecular heterogeneity, and evolving analytical requirements, innovative bioanalytical strategies can generate robust, reliable data that enable confident candidate selection and successful program progression.

What you will learn:

Register Now

Speakers:

Yueting Wu, Ph.D.

Associate Director of DMPK

BioDuro